Cipla Medpro faces claims over side effects of antibiotic
Cipla Medpro faces claims that it failed to inform patients properly about Tavaloxx side effects affecting health outcomes.
Local Medicine Manufacturing and National Health Security
Explore the future of local medicine manufacturing as Sahpra fast-tracks evaluation to secure South Africa's national supply.
New COVID-19 Variant No Threat to South Africa
While the COVID-19 pandemic has subsided from its peak, the virus continues to circulate globally. SA experts demand vaccine access.
Twice-Yearly HIV Jab: Activists Call for Lower Prices
Explore the revolutionary Twice-Yearly HIV Jab, a potential game-changer in HIV prevention that raises important affordability questions.
Counterfeit Medicine Crisis in South Africa’s Public Health System
South Africa is grappling with a quiet, yet deadly crisis: the alarming proliferation of counterfeit and substandard medicines, known as the counterfeit medicine crisis. While the nation faces ongoing health-care challenges like rising drug prices, medicine shortages, and a strained public health system, the influx of fake drugs presents a far more insidious threat. These…...
Adcock Ingram’s Urizone Wins Trademark Battle
Adcock Ingram's Urizone receives legal protection as the court halts Cipla's Furizome, citing trademark infringement.
SAHPRA calls for Increased National Treasury funding
The SA Health Products Regulatory Authority (SAHPRA) has appealed to the National Treasury for more funding, warning of operational risks due to over-reliance on fee income.
SAHPRA to enforce compliance with the B-BBEE Act
SAHPRA will enforce compliance with the B-BBEE Act, affecting all health product license applicants. Stay informed on the changes.